These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29193711)

  • 21. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.
    Jung J; Tawa EA; Muench C; Rosen AD; Rickels K; Lohoff FW
    Psychiatry Res; 2017 Aug; 254():8-11. PubMed ID: 28437668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
    Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
    Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
    Allgulander C; Florea I; Huusom AK
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes.
    Zullino D; Chatton A; Fresard E; Stankovic M; Bondolfi G; Borgeat F; Khazaal Y
    Psychiatr Q; 2015 Mar; 86(1):69-82. PubMed ID: 25464934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
    Meoni P; Hackett D; Lader M
    Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
    Haduch A; Rysz M; Papp M; Daniel WA
    Biochem Pharmacol; 2018 Oct; 156():398-405. PubMed ID: 30195732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
    Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
    Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.
    Kulhan T; Marcincakova Husarova V; Ondrejka I; Farsky I; Nosalova G
    Neuro Endocrinol Lett; 2018 Feb; 38(8):579-585. PubMed ID: 29504736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder.
    Rickels K; Gallop R; Cleary S
    J Clin Psychopharmacol; 2019; 39(3):258-260. PubMed ID: 30932946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.